drugset / Trial / NCT01230762

An Open-Label Study of the Long-Term Safety of Dapoxetine HCl in the Treatment of Rapid Ejaculation

NCT01230762

Phase 3 Completed 1774 enrolled Alza Corporation
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the long-term safety of dapoxetine in men with rapid ejaculation.

Timeline

Start
Primary completion
Completion
2005-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Dapoxetine Small molecule 30 mg Oral
Subject Dapoxetine Small molecule 60 mg Oral